Sanofi stock breaks through its support at €73.25 and extends its decline

Support at €73.25 broken, stock below its three moving averages

Sanofi is down 1.87% at €73.00 during the session, after breaking through its support at €73.25. The stock remains below this level, which constitutes a negative technical signal in an already deteriorated configuration. The price is indeed trading below its three moving averages: the 20-day MA at €75.62 (variance of -3.46%), the 50-day MA at €76.10 (-4.07%) and the 200-day MA at €77.95 (-6.35%).

These three benchmarks form a technical ceiling that weighs on potential rebounds. The RSI at 45 remains in neutral territory, without an oversold signal that would indicate exhaustion of selling pressure. Over the month, the stock has lost 7.53% — one of the weakest performances in the CAC 40 in early afternoon trading, where the index itself is down 0.32%.

The open letter on European pharmaceutical competitiveness as backdrop

On September 22, 2026, the presidents of nine pharmaceutical groups, including Sanofi, published an open letter calling on national leaders to strengthen Europe's attractiveness to the United States and China in terms of sector investments. This text reflects a context of structural pressure on margins and competitiveness of the European pharmaceutical industry, although this diplomatic signal does not directly influence today's quotation. In terms of valuation, according to the consensus of analysts tracked, the stock is trading at approximately 8.5 times expected earnings for the current fiscal year and 8.0 times those of the following fiscal year, with earnings per share growth projected at +5.8% from one fiscal year to the next. The next threshold to monitor remains the resistance at €78.94, well above the current price.